Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy

BACKGROUND: Non-small cell lung cancer (NSCLC) patients treated with first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) almost always acquire resistance, and the development of novel techniques analyzing circulating tumor DNA (ctDNA) have made it possible for liqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yulong, Wang, Anqi, Zhou, Jieqi, Feng, Wei, Shi, Minhua, Xu, Xiao, Zhao, Hongqing, Cai, Liming, Feng, Jian, Lv, Xuedong, Zhang, Xiaodong, Xu, Wenjing, Zhang, Zhengrong, Ma, Guoer, Wang, Jian, Zhou, Tong, Zhao, Dahai, Fang, Haohui, Liu, Zeyi, Huang, Jian-an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943858/
https://www.ncbi.nlm.nih.gov/pubmed/33718183
http://dx.doi.org/10.3389/fonc.2021.621992

Ejemplares similares

Ejemplares similares